Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
International Regulome Consortium continues to grow: Ottawa-led stem cell research group partners with Invitrogen
June 18, 2008
The International Regulome Consortium (IRC) announced today it has signed a non-binding letter of intent with Invitrogen Corporation to develop tools for stem cell research that will aid in the development of new therapies for some of the world’s most debilitating diseases.
Invitrogen will contribute services and technology to help IRC researchers in their goal of mapping the genetic circuit board that regulates how stem cells give rise to specialized cells such as neurons. IRC is a third generation genome project, involving 58 researchers from 34 institutions in 12 countries.
The IRC is led by Dr. Michael Rudnicki, Director and Senior Scientist at the Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute at The Ottawa Hospital. Dr. Rudnicki is also a Professor in the Faculty of Medicine at the University of Ottawa and Scientific Director of the Stem Cell Network.
Links
International Regulome Consortium press release
International Regulome Consortium website
Dr. Michael Rudnicki’s OHRI Scientist Profile
